- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 3769
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 December 2025 | Awaiting development. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2027. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 18 September 2025 | In progress. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2027 when we will write to you about how you can get involved. |
| 08 August 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2026 when we will write to you about how you can get involved. |
| 23 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Naxitamab with GM-CSF within its marketing authorisation for treating relapsed or refractory high-risk neuroblastoma. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
| 01 April 2020 | Topic has been referred |
For further information on our processes and methods, please see our CHTE processes and methods manual